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Background of the Study 
The programmed-death 1 receptor (PD-1)/programmed-death ligand 1 (PD-L1, also called B7-H1, and CD274) pathway regulates T-cell responses and the balance between T-cell activa-
tionand tolerance, and acts as an immunologic checkpoint (1). In normal tissues, PD-L1 is expressed on T cells, B cells, dendritic cells, macrophages, mesenchymal stem cells, and mast cells, 
as well as several hematopoietic cells (2, 3). PD-L1 is also expressed in multiple types of cancers (4), including head and neck squamous cell carcinomas (HNSCC) and, among them, in oral 
squamous cell carcinomas (OSCC; refs. 3, 5, 6). In the tumor microenvironment, PD-L1 expressed in tumor cells binds to the inhibitory receptor PD-1, a member of the B7 family of recep-
tors (7), on activated T cells reaching the tumor [tumor-infiltrating lymphocytes (TIL)], thereby delivering an inhibitory signal to those T cells that ultimately prevents tumor elimination from 
the immune system (3, 8, 9). 
Oral Squamous Cell Carcinoma (OSCC) is the most common type of cancer in the head and neck area. It belongs to the ten most common cancers, and approximately 300,000 new cases 
are diagosed annually worldwide (10). OSCC is associated with poor prognosis and higher morbidity when diagnosed at advanced stages (11), and it has been considered to be a very immu-
nosuppressive cancer. Immunen tolerance is mediated by inhibitory signaling pathways called immune checkpoints. One of the most important immunologic checkpoints is the axis PD-1/PD
-L1 that has been proposed as a potential mechanism facilitating the immunosuppressive phenotype in OSCC (5, 6). Consequently, at least from a theoreticalpoint of view, blockade of the 
PD-1/PD-L1 pathway could effectively reduce tumor growth and improve survival (6). Positive tumor PD-L1 expression determined by immunohistochemistry (IHC) is thought to be predic-
tive of clinical response (12), and thus, the PD-1/PD-L1 checkpoint inhibitors, such as nivolumab and pembrolizumab have demonstrated clinical efficacy in the treatment of advanced 
HNSCC .  
The expression of PD-L1 is up-regulated in many cancers, such as lung, ovary, colon, skin, brain, kidney, esophagus, stomach and breast cancers. Moreover, PD-L1 expression has been as-
sociated with poor prognosis in many malignancies, such as nasopharynx, kidney, esophagus, stomach, pancreas, breast and salivary gland carcinomas, as well as malignant melanoma. 
 
Aim & Objectives of the Study 
The purpose of the present study was to investigate the expression of PD-L1 in OSCC and to establish correlations of PD-L1 expression and clinicopathologic grades , and their impact on patients' s 
survival. 




Well differentiated squamous cell carcino-
ma 
21 
Moderately differentiated squamous cell 
carcinoma 
20 
Poorly differentiated squamous cell carcino-
ma 
12 
A retrospective study was designed. Surgical tissue specimens from 
53 patients with OSCC who underwent surgical treatment with cura-
tive purposes  were retrospectively collected, in accordance to ap-
proved institutional review board guidelines. Clinicopathologic data 
were collected from medical records. Tissue specimens were ob-
tained and representative tissue sections were obtained from archiv-
al, formalin-fixed paraffin-embedded blocks and the histologic  
diagnosis was confirmed by an experienced Pathologist. 
1. The sections were deparaffinized with standard xylene and hydrated through graded alcohols into water. Antigen retrieval was performed by heating 
the sections with Envision Flex Target Retrieval solution, high pH (Dako). Staining was done at room temperature on an automatic staining work-
station (Dako Autostainer Plus, Dako). 
2. Rabbit monoclonal PD-L1 antibody (clone E1L3N, 1:200 dilution; Cell Signaling Technology #13684),  by using the Dako EnVision Flex þVisuali-
zation System (Dako Autostainer). Counterstaining with hematoxylin was the final step. 
3. PD-L1 immunostainings were manually evaluated by three independent observers , with a high level of interobserver concordance (>95%). 
Degree of staining was scored as: 
•3+: extensive staining of the tumour including the invasion front towards the connective tissue 
•2+:  more than 50% of positive staining 
•1+: less than 50% of positive staining 
•0: almost negative 
IHC Staining and Protocol 
SCORE: 0 


























































INTENSITY OF STAINING IN DIFFERENT GRADES OF 






HNSCC has been defined as one of the most highly immune-infiltrated cancer types, and in fact, the most highly NK-
cell and Treg-infiltrated cancer type, although immune infiltration varies depending on several clinical and genetic fea-
tures, such as HPV infection, tumor location within the head and neck region, molecular subtype, mutational smoking 
signature, and genomic instability. PD-L1 is a cell-surface glycoprotein primarily expressed by antigen-presenting cells 
and tumor cells that induces T-cell anergy and apoptosis by engaging its PD-1 receptor. Binding of PD-L1 to its recep-
tor PD-1 inhibits the proliferation of activated T cells, leading to apoptosis or downregulation of cytotoxic T lympho-
cytes (CTL), called "T-cell exhaustion", which results in an escape of tumor cells from T-cell–mediated immune surveil-
lance (2). It is assumed that tumor cells upregulate PD-L1 expression to evade the host immune reaction, thereby in-
creasing their survival rate (31). 
Tumor PD-L1 expression is induced intrinsecally by oncogenic signaling pathways, like the MAPK signaling pathways, 
and extrinsecally by factors from the tumor microenvironment, such as hypoxia, through the induction of the hypoxia-
associated transcription factor HIF1a and cytokine production. 
The prognostic relevance of PD-L1 was confirmed by multivariate analysis in this study, therefore suggesting that pa-
tients with OSCC with high PD-L1 expression might require PD-L1– targeted immunotherapy to improve prognosis 
and clinical outcome. Thus, even though the mechanisms leading to PD-L1 overexpression are not yet fully understood 
(36), clinical data from treatment with PD-1/PD-L1 inhibitors have shown response rates ranging from 10% to 50% in 
HNSCC and other tumor types (11). In a recent meta-analysis, Gandini and colleagues (12) found that the IHC evalua-
tion of tumor PD-L1 expression correlated with clinical response to PD-1/PD-L1 immunotherapy in various cancers, 




In conclusion, patients with OSCC with high PD-L1 expression 
showed a poor prognosis probably due to the activation of PD-1/
PD-L1 pathway that enhances an aggressive tumor phenotype by 
allowing tumor cells to evade the host immune system, thus estab-
lishing a T-cell exhaustion, which ultimately induces a specific tol-
erance. Accordingly, this group of patients with OSCC emerges as 
an ideal candidate for clinical trials of anti-PD-L1 targeted therapy. 
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